THE WOODLANDS, Texas, July 31, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2012.
"Our positive top-line results from the Phase 2b study of LX4211 mark a very important milestone in the advancement of Lexicon's clinical pipeline towards late-stage development," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We believe the robust reductions in hemoglobin A1c, body weight and blood pressure are driven by LX4211's unique, dual mechanism of action and that these findings, combined with the favorable safety profile observed, support progression of LX4211 into Phase 3 development."
SOURCE Lexicon Pharmaceuticals, Inc.
